Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 24 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

33%

8 trials in Phase 3/4

Results Transparency

11%

2 of 19 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (1)
P 1 (7)
P 2 (2)
P 3 (6)
P 4 (2)

Trial Status

Completed19
Active Not Recruiting2
Recruiting1
Not Yet Recruiting1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 19 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT06672016Phase 3Active Not RecruitingPrimary

Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

NCT07351084Completed

Patient Factors Associated With Fragmentation of Copper Intrauterine Devices Requiring Hysteroscopic Removal

NCT03432416Phase 2Completed

Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring

NCT04143659Phase 1Active Not Recruiting

A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception

NCT07222228Phase 2Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception

NCT06394999Phase 3RecruitingPrimary

Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive

NCT03124160Phase 3Completed

Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard

NCT01178125Phase 3Completed

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

NCT01286948Phase 1CompletedPrimary

Prevention of Ovulation Achieved by Single Intra-vaginal Administration of Levogel as Compared to Oral LNG

NCT00377988Completed

A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control

NCT00331071Completed

Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks

NCT00511784Completed

Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.

NCT01833793CompletedPrimary

Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice

NCT02257671Not ApplicableUnknownPrimary

Oral Contraceptives and Economic Behaviour

NCT00258076Phase 1Completed

A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)

NCT00709189Phase 1CompletedPrimary

Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.

NCT00254865Phase 1Completed

A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers

NCT00775086Phase 1CompletedPrimary

Bioequivalence Study of Patches With Different Equilibration Profiles

NCT00258063Phase 1Completed

A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)

NCT00697307CompletedPrimary

Bioequivalence Study of Patches With Different Release Profiles

Scroll to load more

Research Network

Activity Timeline